Byotrol plc
("Byotrol" or the "Company")
Senior Management Appointment
Byotrol plc (AIM: BYOT), the infection prevention technology company, is pleased to announce the appointment of Vivan Pinto as Chief Growth Officer (CGO) of the Company.
Vivan is an experienced commercial leader with a blue-chip career spanning 20 years at Johnson and Johnson, Reckitt Benckiser and Pfizer, where he held senior positions in General Management, Commercial and Marketing across the globe. His most recent position was Area Managing Director for J&J Consumer Health Africa.
At Byotrol, Vivan will be leading and growing our consumer business and will also be central to developing group strategy. His arrival completes a series of recent investments in upgrading Byotrol's operational leadership team, across the sales, marketing, business development, strategy, finance and technology functions.
Vivan graduated from Duke University, North Carolina, with a BSc in Biology before completing a MSc in IP Law from Queen Mary's College and an MBA from Imperial College, both in London. At the date of this announcement, he holds 200,000 ordinary shares of 0.25 pence each in the Company ("Ordinary Shares") representing approximately 0.04 per cent. of the Company.
Commenting on the appointment, David Traynor, CEO of Byotrol plc, said:
"We are delighted to welcome Vivan Pinto into the team. He has an excellent track record in leading and growing very successful businesses across B2B and B2C. We are all looking forward to working with him."
Enquiries:
Byotrol Plc | |
John Langlands - Chairman David Traynor - Chief Executive Chris Sedwell - Chief Finance Officer | +44 (0)1925 742 000 |
| |
finnCap (Nominated Adviser and Broker) | +44 (0)20 7220 0500 |
Geoff Nash/Kate Bannatyne/George Dollemore - Corporate Finance | |
Richard Chambers - ECM | |
| |
Flagstaff Strategic and Investor Communications | +44 (0)20 7129 1474 |
Tim Thompson/Andrea Seymour/Fergus Mellon
|
|
Notes to Editors:
Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and control company, operating globally in the Healthcare, Industrial, Food and Consumer sectors, providing low toxicity products with a broad-based and targeted efficacy across all microbial classes; bacteria, viruses (including coronavirus), fungi, moulds, mycobacteria and algae.
Byotrol's products can be used stand-alone or as ingredients within existing products, where they can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.
Byotrol develops and commercialises technologies that create easier, safer and cleaner lives for everyone.
For more information, please go to byotrol.co.uk
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.